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Among the 11 members of the IL-1 family cytokines, the precursors of IL-1α, IL-1β, and IL-33
have relatively long N-terminal pro-sequences of approximately 100 amino acid residues
prior to the N-terminus of the mature forms. Compared to the mature forms secreted from
the cell, 80–90% of the primary translation product is in the intracellular compartment in
the precursor form. However, the precursors are readily released from cells during infec-
tions but also with non-infectious conditions such a hypoxia and trauma. In this setting, the
precursors act rapidly as “alarmins” in the absence of a processing mechanism to remove
the pro-sequence and generate a mature form. In the case of IL-1α, the release of the pre-
cursor activates adjacent cells via receptor-mediated signaling. However, there are no data
comparing the specific activity of the IL-1α precursor to the mature form. In the present
study, we compared the precursor and mature forms of recombinant human IL-1α, IL-1β,
and IL-33 proteins on the induction of cytokines from A549 cells as well as from human
peripheral blood mononuclear cells (PBMC). Similar to the mature form, the IL-1α precursor
was active in inducing IL-6 and TNFα, whereas the precursor forms of IL-1β and IL-33 were
not active. On PBMC, precursor and mature IL-1α at 0.04 and 0.2 nM were equally active in
inducing IL-6. Given the fact that during necrotic cell death, the IL-1α precursor is released
intact and triggers IL-1 receptors on tissue macrophages, these data identify the precursor
form of IL-1α as a key player in sterile inflammation.
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INTRODUCTION
Among the 11 members of IL-1 family cytokines, 10 have no signal
peptide, the exception being the IL-1 receptor antagonist (IL-1Ra)
(1). The signal peptide in IL-1Ra allows the cell to release the antag-
onist as an active molecule without a requirement for processing of
the IL-1Ra precursor whereas all other members of the IL-1 family
require processing from an inactive precursor to an active cytokine.
Of these 10 leaderless forms, IL-1α, IL-1β, and IL-33 each have pro-
pieces of approximately 100 amino acid residues at their respective
N-termini, whereas the other members of IL-1 family cytokines,
have shorter pro-pieces, the IL-36 subfamily has the shortest. IL-
1α was the first cytokine shown to translocate to the nucleus and
the pro-piece contains a nuclear localization sequence (LKKRRL),
which binds to chromatin and acts as transcription factor (2–4).
Although during apoptosis, the intracellular IL-1α precursor binds
tightly to chromatin (4), during necrosis, the precursor dissociates
from the chromatin is released from the cell in the precursor form
(4). The IL-33 precursor also acts as a transcription factor and is
chromatin bound (5); IL-33 is also released from dying cells where
extracellular processing takes place by serine proteases (6, 7). The
precursor forms for IL-1β and IL-18 are inactive; processing to
an active cytokine can take place intracellularly by caspase-1 but
extracellularly by neutrophil-derived proteinase-3 (8–10).
Damage (or danger)-associated molecular pattern molecules
(DAMPs) are nuclear or cytosolic proteins from necrotic cells or
tissues, dying tumor cells or released from cells by an infectious
process. DAMP’s released from the cells can activate surface recep-
tors on distant or adjacent cells. Because DAMP’s rapidly initiate
inflammation cell in the absence of proper secretion mechanisms,
the term “alarmin” is often used for categorizing such endoge-
nous molecule as proposed by Oppenheim (11). The released
intracellular proteins have immediate effects on cells expressing
receptors involved in inflammation, host defense, and tissue repair.
Pathogen-associated molecular patterns (PAMPs) initiate inflam-
mation by an infectious pathogen, most commonly via Toll-Like
Receptors (TLR) (12).
In many ways, the hallmark of DAMP activity is sterile inflam-
mation with neutrophil recruitment into the area of the damaged
tissues, for example, in myocardial infarction, acute lung injury
and cerebrovascular accident (stroke). In acute lung injury, the
type II epithelial cells contain constitutive IL-1α precursor and
when released, mediates local inflammation, which is prevented
by IL-1 receptor blockade (13, 14). In a mouse model of DAMP
activity from necrotic tumor cells injected intraperitoneally, there
is neutrophilic inflammation but also elevation of hepatic enzyme
alanine aminotransferase (ALT) (15). The inflammation was
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observed in wild-type (WT) mice but not in mice deficient in the
IL-1 receptor type 1 (IL-1R1) (15). Furthermore, antibodies to IL-
1α rather than to IL-1β blocked the response and the inflammation
was still observed in mice deficient in TLR (15). In those studies,
the molecular nature of the IL-1α, i.e., whether the precursor or the
mature form, was not determined. However, in another study (4)
keratinocytes exposed to prolonged hypoxia in vitro released cellu-
lar contents containing IL-1αwith a molecular weight of 30,000 Da
consistent with the precursor form. Moreover, in vivo neutrophilic
response to these unfractionated supernatants was blocked by an
IL-1α specific neutralizing antibody (16), suggesting that the IL-
1α precursor is active. Since IL-1, either IL-1α or IL-1β, promotes
IL-17 production by T cells, alarmin-mediated immune responses
may be an important endogenous activator of pathogenic T cells
in autoimmune diseases (17, 18).
Because the precursor forms of IL-1α, IL-1β, and IL-33 are
released as DAMPs and because the biological responses to DAMP-
mediated sterile inflammation plays a major role in many ischemic
diseases, we compared the specific biological activities in molar
ratio of precursor and mature forms using cytokine responses
from a mesenchymal cell (lung type II epithelial cell) and a
hematopoietic cell (blood monocytes).
MATERIALS AND METHODS
RECOMBINANT CYTOKINES AND ANTIBODIES
The recombinant proteins were expressed in E. coli with six
N-terminal histidine tags and purified over a mini-Talon chro-
matography, ion-exchange for IL-1β or HPLC for IL-1α and
IL-33 as described (6). Purity was assessed by silver staining of
PAGE (Figure 1). The endotoxin content was less that 1 EU/mg.
The N-termini for mature IL-1β was at 117 (caspase-1 site),
for mature IL-1α was 115 and for IL-33 111 (19). Anti-human
IL-1α was a kind gift of XBiotech (Austin, TX, USA) and IL-
1Ra (anakinra) was purchased from R&D Systems, Minneapolis,
MN, USA.
CELL CULTURES
Human peripheral blood mononuclear cells (PBMCs) were iso-
lated by density centrifugation of blood over Ficoll-Paque™ PLUS
(GE, Piscataway, NJ, USA). PBMCs were washed with saline and
resuspended in tissue culture medium (RPMI 1640) containing
10% FCS at 5 million cells/mL. The cells were seeded in 100µL
volumes in 96-well flat-bottom microtiter plates and the recombi-
nant cytokines were added in RPMI-10%FCS. In some studies, the
recombinant cytokines were preincubated with anti-IL-1α anti-
body (XBiotech, Austin, TX, USA) before being added to the cells.
In other studies, IL-1Ra was added to the cells before the recom-
binant cytokines. After 24 h of incubation, the supernatants were
removed as assayed for IL-6, IL-8, or TNFα using specific ELISA
(R&D Systems).
Human A549 cells were cultured as described previously (20).
Recombinant cytokines were added in presence or absence of anti-
IL-1α or IL-1Ra as described above. After 24 h of stimulation, the
levels of IL-6 were measured (R&D Systems). The human mast
cell responses to IL-33 were measured in the HMC-1 cell line as
described previously (6, 19). After 24 h of incubation with mature
FIGURE 1 | Expression and purification of recombinant cytokines. Six
different recombinant cytokine proteins were expressed in E. coli as
indicated. Precursor (pro) IL-1α and mature (mat) IL-1α (200 ng/lane) in left
panel, proIL-1β and mature IL-1β (100 ng/lane) in middle panel, and proIL-33
and mature IL-33 (500 ng/lane) were purified by affinity chromatography and
then subjected to 10% SDS-PAGE. The purity of each recombinant protein
was visualized by silver staining. The data represents one of three
independent experiments.
or precursor IL-33, IL-8 was measured in the supernatants (R&D
Systems).
WESTERN BLOTS
For detection of precursor and mature IL-1α, 30µL each of con-
centrated (×10) overnight A549 cell culture supernatants were
used for 10% SDS-PAGE. The samples were transferred to nitro-
cellulose membrane and the membranes were blocked in 3%
BSA/TBST. Anti-IL-1α antibodies (R&D Systems) were used for
the western blot. A peroxidase-conjugated secondary antibody
(Jackson Immuno Research Laboratories, West Grove, PA, USA)
was used to develop the blots along with Supex (Neuronex, Seoul
Korea) and an LAS-4000 imaging device (Fujifilm, Japan).
RT-PCR OF IL-1 RECEPTORS
Total RNA was isolated with Tri-Reagent (Sigma, St. Louis,
MO, USA) from human lung carcinoma A549 cells or
PBMCs. A pair of human IL-1R1 sense primer, 5′-
GGCTGATAAATGCAAGGAACG-3′ and reverse primer, 5′-
CCTAGCACTGGGTCATCTTC-3′, of human IL-1R3 primer,
5′-GAACATCAGCAGGCCCTAGA-3′ and reverse primer, 5′-
GGGGAATTGAAACAGCTGTCT-3′, and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) sense primer,5′-ACCACAGT
CCATGCCATCAC-3′ and reverse primer, 5′-TCCACCACCCTGT
TGCTGTA-3′, was used for the RT-PCR. MMLV-RT (Beams Bio,
Korea) was used for converting 2µg of total RNA to first strand
cDNA, and then PCR reaction was performed at 94°C for 45 s,
70°C for 2 min, and 59°C for 1 min for 30 cycles.
STATISTICAL ANALYSIS
The data is expressed as mean± SEM. Statistical significance of
differences was analyzed by unpaired, two-tailed Student’s t test.
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RESULTS
PRECURSOR IL-1α IS ACTIVE WHEREAS PRECURSOR IL-1β IS INACTIVE
We expressed six different recombinant IL-1 family cytokines
(precursor IL-1α, mature IL-1α, precursor IL-1β, mature IL-1β,
precursor IL-33, and mature IL-33) and purified the recombinant
proteins by two-steps of chromatography as described previously
(6). Each recombinant cytokine was examined for purity by 10%
SDS-PAGE and silver staining, and all six cytokines appeared as
primarily a single band (Figure 1). We examined the activity of
precursor and mature forms of IL-1α compared to the precursor
and mature forms of IL-1β. A549 human lung carcinoma cells
were stimulated for 24 h with increasing concentrations of each
form. As shown in Figure 2A, precursor and mature forms of
IL-1α were active in a dose-dependent manner. Both recombi-
nant proteins induced IL-6, although mature IL-1α was twice as
active compared to the precursor at 0.04 or 0.2 nM concentration.
The levels reached statistical significance for mature and precursor
IL-1α-induced IL-6 at 0.04 or 0.2 nM, respectively. Similar experi-
ments were performed comparing precursor and mature forms of
IL-1β. Mature IL-1β was highly active, but precursor IL-1β failed
to induce IL-6 production in A549 cells (Figure 2B).
Next we used western blots of the A549 cell supernatant of
untreated control, precursor IL-1α, and mature IL-1α in order to
demonstrate that the precursor IL-1α-mediated IL-6 production
was not due to maturation of precursor IL-1α during overnight
treatment. As shown in Figure 2A, precursor IL-1α remained
intact (left panel including untreated control, ctl) whereas mature
IL-1α decreased when compared to that of recombinant proteins
(right panel).
We next compared the biological activity of precursor and
mature forms of IL-1α on primary human PBMCs. As shown
in Figure 2C, both precursor and mature IL-1α were active and
these data are similar to the findings depicted in Figure 2A.
However, compared to the activity of mature IL-1α on PBMCs-
induced IL-6 production, the induction of IL-6 by mature IL-1β
on PBMC was less for each concentration (Figures 2C,D). For
example, at 0.04 nM of mature IL-1α-mediated IL-6 from PBMC
was 1.5 ng/mL, but that of IL-1β was only 0.2 ng/mL from PBMC.
The reduced activity by mature IL-1β on PBMCs is consistent
with the presence of the IL-1 receptor-2 on monocytes. The IL-
1R2 is non-signaling decoy receptor, which dampens IL-1β driven
inflammation (21) and preferentially binds mature IL-1β but not
IL-1α (22). In fact, comparing the activity on PBMC and A549
cells, precursor and mature IL-1α induced considerably more IL-
6 at all concentrations on PBMC (Figures 2A,C). In the absence
of the IL-1R2, IL-1α, and IL-1β signal via the complex of the
FIGURE 2 | Comparison of precursor and mature forms of IL-1α and
IL-1β on IL-6 production. (A) Mean±SEM IL-6 supernatant levels induced
in A549 cells after 24 h of incubated with IL-1α precursor or mature forms
and (B) by IL-1β precursor or mature forms at concentrations indicated
under the horizontal axis. Inset in (B) shows the RT-PCR product of IL-1R1
and IL-1R3 in A549 cells. (C) Mean±SEM IL-6 supernatant levels from
PBMCs after 24 h of incubation with IL-1α forms and (D) by IL-1β at
concentrations indicated under the horizontal axis. Inset in (D) shows PCR
product of IL-1R1 and IL-1R3 in PBMCs. *p<0.05; **p<0.01;
***p<0.001 compared to control (cont). RT-PCR products shown are
representative of one of two independent experiments. IL-6 data from
A549 cells shown are one of two independent experiments performed in
triplicate. PBMC data are representative of one of two donors performed
in triplicate.
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IL-1R1 and IL-1R3, also known at the IL-1R accessory protein
(also known as IL-1R3). Both receptor molecules are expressed
in A549 cells and PBMCs, although IL-1R1 expression was more
prominent than that of IL-1R3 (Figures 2B,D).
PRECURSOR IL-1α IS NEUTRALIZED BY AN ANTI-IL-1α ANTIBODY
Considering that the N-terminal domain of the IL-1α precursor
contains 115 amino acids, which are not present in the mature
form, tertiary folding of the IL-1α precursor may be different from
that of the mature form and hence the binding epitopes by anti-IL-
1α may not be the same. Therefore, we tested whether the human
monoclonal antibody to IL-1α neutralized the precursor form of
IL-1α. This antibody is presently be studied in several clinical tri-
als, including type-2 diabetes, psoriasis, and cancer cachexia, as
reviewed in Ref. (23). Precursor or mature IL-1α at 0.5 nM was
preincubated for 30 min with increasing molar excesses of anti-IL-
1α (XBiotech, Austin, TX, USA). The mixtures were then added
to A549 cells and after 24 h, the levels of IL-6 were measured
in the supernatants. Both precursor and mature IL-1α-induced
IL-6 production was inhibited by the antibody (Figure 3A). At
equimolar concentrations of antibody to IL-1α, the reduction
was approximately 50% for precursor and 60% for mature form.
Upon increasing the molar excess of the antibody to fivefold, there
was a 80% reduction in IL-1α-induced IL-6 and at a increase to
25, IL-6 decreased further. As expected, mature IL-1β was not
inhibited by anti-IL-1α (Figure 3B). Similar to A549 cells assay,
precursor and mature IL-1α-induced IL-6 production from PBMC
was specifically inhibited by the anti-IL-1α antibody (Figure 3C),
whereas mature IL-1β-induced IL-6 from PBMC was not affected
by anti-IL-1α (Figure 3D).
REGULATION OF TNFα BY IL-1α AND IL-1β
Since IL-1 induces TNFα in vivo and in vitro (24), we next exam-
ined the induction of TNFα by precursor and mature forms of
IL-1α and IL-1β on PBMC. As shown in Figure 4A, both mature
and precursor forms of IL-1α induced TNFα, although the mature
form at low concentrations (0.04 and 0.2 nM) induced signifi-
cantly more TNFα compared to the precursor. Only mature IL-1β
induced TNFα from PBMC but this induction was low and only
observed at a concentration of 1 nM (Figure 4B). The low induc-
tion by mature IL-1β is likely due to the presence of the IL-1R2
on monocytes in the PBMC cultures as mentioned above. Unlike
PBMCs, A549 cells failed to produce TNFα when stimulated by
either IL-1α or IL-1β at all concentrations (data not shown).
Anti-IL-1α reduced the induction of TNFα by either mature
or precursor IL-1α (Figure 4C). In contrast to the effect of this
antibody on IL-1α on A549 cells, a molar excess of 5 and 25
was required to neutralize IL-1α activity on PBMC. As shown
in Figure 4D, the antibody to IL-1α has no effect on the activity
of mature IL-1β.
FIGURE 3 | Inhibition of IL-1 induced IL-6 by precursor and mature
forms by anti-IL-1α antibody. Anti-IL-1α antibody was first incubated
with either precursor or mature form of IL-1α or IL-1β before being added
to cells. The molar ratio (MR) of antibody to ligand is indicated under the
horizontal axis. (A) Mean±SEM IL-6 supernatant levels induced in A549
cells after 24 h of incubated with IL-1α forms and (B) by IL-1β forms.
(C) Mean±SEM IL-6 supernatant levels from PBMCs after 24 h of
incubation with IL-1α forms and (D) with IL-1β forms. *p<0.05;
**p<0.01; ***p<0.001 compared to control (cont). IL-6 data from
A549 cells shown are one of two independent experiments performed
in triplicate. PBMC data are representative of one of two donors
performed in triplicate.
Frontiers in Immunology | Inflammation November 2013 | Volume 4 | Article 391 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kim et al. Precursor IL-1 family cytokine activities
FIGURE 4 | IL-1α and IL-1β-mediated regulation of humanTNFα in PBMCs.
(A) The cell culture supernatants of PBMCs treated with precursor or mature
recombinant IL-1α from Figure 2C and (B) precursor or mature recombinant
IL-1β from Figure 2D were used for TNFα levels. Concentrations of the
recombinant cytokines are indicated under the horizontal axis. (C) The
inhibition of anti-IL-1α in precursor or mature recombinant IL-1α-induced TNFα
levels (D) that of precursor or mature recombinant IL-1β-induced TNFα levels
were measured in supernatants from Figures 3C,D, respectively. Data are
mean±SEM; *p<0.05; **p<0.01; ***p<0.001 compared to control (cont).
PBMC data are representative of one of two donors performed in triplicate.
IL-1RA ABOLISHES IL-1α AND IL-1β ACTIVITY
IL-1 receptor antagonist (anakinra) is used to treat a broad spec-
trum of acute and chronic inflammatory diseases, as reviewed in
Ref. (23) and since IL-1Ra blocks the IL-1R1, it remains unknown
how many diseases that are controlled by anakinra are due to pre-
vention of IL-1αor IL-1β activity; furthermore, how many diseases
are due to the activity of the IL-1α precursor? This is particularly
an important issue since little is known of the binding of the IL-1α
precursor to the IL-R1 compared to the binding of mature IL-
1α, IL-1Ra, and mature IL-1β (25). The rationale for testing the
ability of the IL-1Ra to block the responses provides indirect evi-
dence that precursor IL-1α, mature IL-1α, and mature IL-1β share
the same receptor since IL-1Ra binds solely to IL-1R1. When we
added IL-1Ra to A549 cells at 1:1 molar ratio, IL-6 induction was
completely abolished (Figure 5).
We next reduced the concentrations of IL-1Ra in order
to establish a complete dose-response of inhibition by the
antagonist. As shown in Figure 5, at a low molar ratio of
0.25, IL-1Ra reduced IL-6 production when stimulated by
either the IL-1α precursor, mature IL-1α, or mature IL-1β
induced IL-6 production in A549 (p< 0.05). The reduction
by IL-1Ra of IL-6 production by mature IL-1β in A549 cells
(Figure 5B) was more effective than by IL-1α (Figure 5A).
Similar experiments with human PBMCs exhibited that IL-1α-
induced IL-6 (Figure 5C) and IL-1β-induced IL-6 (Figure 5D)
were suppressed by IL-1Ra. In addition, we examined the
effect of IL-1Ra on precursor or mature IL-1α and mature
IL-1β-induced TNFα production. As shown in Figures 6A,B,
TNFα was also inhibited by IL-1Ra and nearly absent by
equimolar IL-1Ra.
ACTIVITY OF PRECURSOR AND MATURE IL-33
IL-33, another member of IL-1 family, acts as an alarmin (26–31).
Precursor and mature forms of recombinant IL-33 were added to
A549 cells and PBMCs. Neither precursor nor mature IL-33 were
active on these cells (data not shown). In contrast, the human
mast cell-1 line (HMC-1), which responds to IL-33, was assessed
for activity. As shown in Figure 7, the mature form but not the pre-
cursor of IL-33 was active but did not reach statistical significance
until 1.3 nM concentration.
DISCUSSION
Intracellular contents contain several known alarmins, each of
which can initiate inflammatory responses via specific cell surface
receptors; these include high mobility group box-1 (HMGB-1),
members of the IL-1 family, cytosolic calcium-binding proteins
of the S100 family, heat-shock proteins 70/90, S100 proteins,
peroxiredoxin-1, and nucleosomes (32). For example, HMGB-1
binds to the cell surface scavenger receptor (RAGE) and IL-1α
binds to the IL-1R1. Identification which and to what extent of
the myriad of intracellular alarmins released from necrotic cells
accounts for the inflammation is a daunting task. In the case of
IL-1, specific antibody neutralization has been used to distinguish
IL-1α from IL-1β (15, 16).
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FIGURE 5 | IL-1Ra inhibition of precursor and mature forms of IL-1α
and IL-1β activity. Prior to stimulation with IL-1 (0.5 nM), increasing
concentrations of IL-1Ra were added to cells and are indicated as molar
excess of IL-1Ra to IL-1 under the horizontal axis as molar ratio (MR).
A549 cells were stimulated with 0.5 nM of precursor or mature
recombinant IL-1α (A) and 0.5 nM of precursor or mature recombinant
IL-1β (B) in the presence of absence of IL-1Ra. Similar experiments of
human PBMCs were performed with 0.5 nM of precursor or mature
recombinant IL-1α (C) and 0.5 nM of precursor or mature recombinant
IL-1β (D). IL-6 levels in the supernatants represent mean±SEM;
*p<0.05; **p<0.01; ***p<0.001) compared to control (cont). IL-6 data
from A549 cells shown are one of two independent experiments
performed in triplicate. PBMC data are representative of one of two
donors performed in triplicate.
FIGURE 6 | Inhibition of IL-1α or IL-1β inducedTNFα by IL-1Ra. Prior to
stimulation with IL-1α or IL-1β, increasing concentrations of IL-1Ra were added
to cells indicated as molar excess of IL-1Ra to IL-1 under the horizontal axis as
molar ratio (MR). PBMC cells were stimulated with 0.5 nM of precursor or
mature recombinant IL-1α (A) and in (B) 1.0 nM of precursor or mature
recombinant IL-1β. TNFα levels in the supernatants represent mean±SEM;
*p<0.05; **p<0.01; ***p< 0.001) compared to control (cont). PBMC data
are representative of one of two donors performed in triplicate.
However, the identification does not reveal the molecular
nature of the cytokine linked to biological activity. For example,
when the precursors for IL-1β or IL-1α or IL-33 are released from
necrotic cells into a neutrophil-rich microenvironment, extracel-
lular processing can take place generating one or more mature
forms with different levels of activity (7–9). Indeed, the biological
and receptor binding activities of 23 unique amino acid sequences
of mature human IL-1α (111–270) were expressed in E. coli and
compared with WT the activity of the mature molecule. The study
identified several sequences along one face of the molecule which
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FIGURE 7 | Mean±SEM levels of IL-8 released from human HMC-1
cells. HMC-1 cells were stimulated for 24 h with increasing concentrations
of either mature or precursor form of IL-33 as indicated under the horizontal
axis (*p< 0.05; ***p<0.001). Representative data from one of two
independent experiments performed in triplicate are shown.
are distinct from regions thought to bind to the IL-1 receptor (33).
In the present study, we compared the biological activity of recom-
binant IL-1α, IL-1β, and IL-33 precursors to the activity as mature
proteins using a biologically relevant assay of cytokine production
from human lung epithelial A549 cells and PBMCs.
The IL-1β precursor was consistently without activity on A549
cells and PBMC whereas the mature form with the N-terminus at
the caspase-1 cleavage site (34) was active. Nevertheless, in vivo the
IL-1β precursor can be processed extracellularly by proteinase-3
and elastase into an active cytokine (9, 35). There is no caspase-1
cleavage site in the IL-1α precursor; cleavage is by a membrane
associated calpain results in a 17,000 Da peptide. The N-terminus
of the calpain cleavage product is assumed to be the same as that
the IL-1α purified from the supernatants of a mouse cell line (36).
However, it remains unclear how calpain is activated. For IL-33,
extracellular processing by serine proteases generate several N-
termini with varying degrees of activity (7). In the case of the
precursor forms of IL-1α and IL-33, N-terminal pro-sequence
has another function, binding to nucleic DNA and therefore
participating in transcription (3, 5).
We also know from many studies that the IL-1α precursor is
constitutive in most cells from healthy human subjects, particu-
larly epithelial cells of the entire intestinal, respiratory, and urinary
tracts as well as all keratinocytes. Thus damage or hypoxia in these
tissues results in IL-1αmediated inflammation. In fact, the demon-
stration of the specific activity of recombinant IL-1α precursor in
terms of effective concentrations supports other studies on the
role of IL-1α in inducing sterile inflammation. For example, oth-
ers have reported that cellular contents release by high heat (15)
or prolonged exposure to hypoxic conditions (4, 16) are due to
IL-1α, not IL-1β and not to TLR.
Thus, the IL-1α precursor emerges as a key alarmin from
dying cells. Until the present study, there was no detailed com-
parison demonstrating that the IL-1α precursor can be as active
as the processed form of the cytokine. This is clearly shown in
Figure 2C examining the induction of IL-6 from PBMC. Others
have reported that mature IL-1α is more active than the precursor
using a complex assay for IL-1 that is IL-1-augementation of IL-
2 production from EL4 cells (37). In that study, the investigators
encountered significant difficulties with the activity of N-terminal
his-tagged mature IL-1α due to aggregation. To circumvent the
problem, the precursor was cleaved with calpain and the com-
parison of activities was made between the precursor and the
calpain-generated mature IL-1α. In contract, our studies directly
assessed the active recombinant forms in a direct assay on A549
cells or PBMC. In A549 cells, mature IL-1α is more active than the
precursor but on PBMC, they were equally active. In terms of clin-
ical implications of these findings, progression of inflammation
with an ischemic event followed by re-perfusion, the inflamma-
tion reaches a maximal level on day 3 and at that time, IL-1β rather
than IL-1α dominates the inflammation. Thus, the IL-1α precur-
sor triggers the IL-1R1 on the resident macrophage population in
the affected tissue, producing IL-1β as well as chemokines as the
post-necrotic inflammatory response progresses.
In addition to sterile inflammation induced by hypoxic or
ischemic events, there is role for the IL-1α precursor in model
of vascular inflammation such as the vasculitis of lupus. Here the
release of apoptotic bodies released dying human endothelial cells
contain the precursor as well as a processed form of IL-1α (38).
These apoptotic bodies are highly inflammatory in vivo and are
due to IL-1α and not IL-1β (38). Another role for inflammation
due to the IL-1α precursor is in dying tumors. As tumors outgrow
their vascular supply, necrosis takes place and here the source of
the IL-1α precursor is the tumor itself. Proof of this mechanism
comes from a human trial in which patients with advanced cancer
are treated with anti-IL-1α monoclonal human antibody. These
patients are markedly cachectic and have low lean body mass.
Upon treatment with anti-IL-1α, many patients start to reverse the
loss in mean mass and live longer compared to untreated patients
(39). The mechanism of this loss in body mass appears to be a
reduction in inflammation as those patients who respond to anti-
IL-1α have a fall in serum IL-6 whereas those who do not reverse
the weight loss have higher IL-6 levels (39).
Not all patients responded to anti-IL-1α treatment, which raises
the issue of the control of intracellular IL-1α activity in tumor cells.
It is known that some forms of tissue necrosis are associated with
inflammation whereas others are not (37). Thus, one can assume
that the activity of IL-1αmaybe under a control mechanism which
is cell specific. Indeed, it has been reported that intracellular IL-1α
precursor is bound to intracellular IL-1R2 and that this complex
inhibits the activity of precursor IL-1α (37). In those cells with-
out constitutive IL-1R2, the IL-1α precursor is active. One can
conclude from that study that necrotic cells without constitutive
IL-1R2 are likely to induce inflammation due to the activity of
the IL-1α precursor whereas those with IL-1R2 are less likely to be
inflammatory.
The release of alarmins such as the IL-1α precursor initially
target adjacent stromal cells, resident tissue macrophages, and
dendritic cells. In turn, these cells release chemokines, which then
recruit the infiltration of inflammatory cells such as monocytes
and neutrophils into the area of damage, thus the initial event such
as ischemia in an organ increases with the infiltration of cells from
the periphery. The secondary cytokines such as IL-6 released from
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stromal cells by the activity of the IL-1α precursor gains access to
the circulation and stimulates the liver to synthesize acute phase
proteins such as C reactive protein and suppress the synthesis of
albumin.
Since is released from tumor cells and necrotic cells in the con-
text of intracellular cytokines, IL-33 can be seen as a novel of
alarmin (26–31). However, our data (Figure 6) show that the pre-
cursor form of IL-33 is not active on mast cells compared to the
processed forms; it is likely that IL-33 has limited activities due
to its receptor expression pattern in different immune cell linages
including non-immune cell linage (40). Although precursor IL-33
possesses biological activity, unlike precursor IL-1α, the impact of
effects could be less because only particular immune cells linages
respond to IL-33. In other studies, IL-33 exhibits a weak activity
as a precursor compared to mature IL-33 (6, 19, 40).
In summary, our data of precursor and mature recombinant
IL-1α, IL-1β, and IL-33 proteins demonstrate that the precursor
from of IL-1α is a key alarmin since precursor protein without
the processing of maturation such as inflammasome dependent
or independent pathways. The biological activity of IL-1α as an
alarmin is due to the rapid release of intracellular molecules in
the absence of processing mechanisms, this initiating downstream
inflammation. Unlike precursor IL-1α, precursor IL-1β, and IL-
33 failed to exhibit biological activities though mature IL-1β and
IL-33 were highly active.
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